Utility of 99mTc-Sestamibi Heart/Liver Uptake Ratio in Screening Nonalcoholic Fatty Liver Disease During Myocardial Perfusion Imaging
- 1 December 2023
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 38 (10), 663-669
- https://doi.org/10.1089/cbr.2022.0062
Abstract
Purpose: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic hepatic disease worldwide, with functional impairment of the mitochondria occurring from early stages. Technetium-99m methoxy-isobutyl-isonitrile (99mTc-MIBI) is a lipophilic agent trapped in the mitochondria. This study aims to evaluate the utility of 99mTc-MIBI heart/liver uptake ratio in screening for NAFLD during myocardial perfusion imaging (MPI). Methods: Seventy eligible patients underwent a 2-d rest/stress 99mTc-MIBI scan with a 2-min planar image acquired in rest phase, at 30, 60, and 120 min postradiotracer administration. Heart/liver uptake ratio was calculated by placing identical regions of interest on the heart and liver dome. All patients underwent liver ultrasound and were allocated into groups A, having NAFLD; and B, healthy individuals without NAFLD. Results: Mean count per pixel heart/liver ratios gradually increased over time in either group; nonetheless the values were significantly higher in group A, regardless of acquisition timing; with the p-value equal to 0.007, 0.014, and 0.010 at 30, 60, and 120 min, respectively. Conclusion: Determining 99mTc-MIBI heart/liver uptake ratio during rest phase in patients undergoing MPI may be a useful, noninvasive screening method for NAFLD; with no additional cost, radiation burden, or adverse effects in these patients. Trial registration number: IR.SBMU.MSP.REC.1398.308.Keywords
This publication has 23 references indexed in Scilit:
- Diagnosis of non-alcoholic fatty liver disease (NAFLD)Diabetologia, 2016
- EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revisionEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Noninvasive imaging assessment of non-alcoholic fatty liver disease: Focus on liver scintigraphyWorld Journal of Gastroenterology, 2015
- Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patientsLiver International, 2015
- Diagnostic accuracy of a noninvasive hepatic ultrasound score for non-alcoholic fatty liver disease (NAFLD) in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)Sao Paulo Medical Journal, 2015
- Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver diseaseAlimentary Pharmacology & Therapeutics, 2014
- Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetesBiomedical Reports, 2014
- Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patientsThe Esophagus, 2013
- From NAFLD in clinical practice to answers from guidelinesJournal of Hepatology, 2013
- Usefulness of Technetium‐99 m‐2‐methoxy‐isobutyl‐isonitrile liver scintigraphy for evaluating disease activity of non‐alcoholic fatty liver diseaseHepatology Research, 2012